Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Cristina Saura, Dominik Hlauschek, Mafalda Oliveira, Dimitrios Zardavas, Anita Jallitsch-Halper, Lorena de la Peña, Paolo Nuciforo, Alberto Ballestrero, Peter Dubsky, Janine M. Lombard, Peter Vuylsteke, Carlos A. Castaneda, Marco Colleoni, Giuliano Santos Borges, Eva Ciruelos, Monica Fornier, Katalin Boer, Aditya Bardia, Timothy R. Wilson, Thomas J. StoutJerry Y. Hsu, Yi Shi, Martine Piccart, Michael Gnant, José Baselga, Evandro de Azambuja

Research output: Contribution to journalArticlepeer-review

67 Scopus citations


Background: Endocrine therapy-based neoadjuvant treatment for luminal breast cancer allows efficient testing of new combinations before surgery. The activation of the phosphatidylinositol-3-kinase (PI3K) pathway is a known mechanism of resistance to endocrine therapy. Taselisib is an oral, selective PI3K inhibitor with enhanced activity against PIK3CA-mutant cancer cells. The LORELEI trial tested whether taselisib in combination with letrozole would result in an increased proportion of objective responses and pathological complete responses. Methods: In this multicentre, randomised, double-blind, parallel-cohort, placebo-controlled phase 2, study, we enrolled postmenopausal women (aged ≥18 years) with histologically confirmed, oestrogen receptor (ER)-positive, HER2-negative, stage I–III, operable breast cancer, from 85 hospitals in 22 countries worldwide. To be eligible, patients had have an Eastern Cooperative Oncology Group (ECOG) performance status 0–1, adequate organ function, and had to have evaluable tumour tissue for PIK3CA genotyping. Patients were randomly assigned (1:1) by means of a permuted block algorithm (block size of four) via an interactive voice or web-based response system, to receive letrozole (2·5 mg/day orally, continuously) with either 4 mg of oral taselisib or placebo (on a 5 days-on, 2 days-off schedule) for 16 weeks, followed by surgery. Randomisation was stratified by tumour size and nodal status. Site staff, patients, and the sponsor were masked to treatment assignment. Coprimary endpoints were the proportion of patients who achieved an objective response by centrally assessed breast MRI and a locally assessed pathological complete response in the breast and axilla (ypT0/Tis, ypN0) at surgery in all randomly assigned patients and in patients with PIK3CA-mutant tumours. Analyses were done in the intention-to-treat population. This trial is registered with, number NCT02273973, and is closed to accrual. Findings: Between Nov 12, 2014, and Aug 12, 2016, 334 participants were enrolled and randomly assigned to receive letrozole and placebo (n=168) or letrozole and taselisib (n=166). Median follow-up was 4·9 months (IQR 4·7–5·1). The study met one of its primary endpoints: the addition of taselisib to letrozole was associated with a higher proportion of patients achieving an objective response in all randomly assigned patients (66 [39%] of 168 patients in the placebo group vs 83 [50%] of 166 in the taselisib group; odds ratio [OR] 1·55, 95% CI 1·00–2·38; p=0·049) and in the PIK3CA-mutant subset (30 [38%] of 79 vs 41 [56%] of 73; OR 2·03, 95% CI 1·06–3·88; p=0·033). No significant differences were observed in pathological complete response between the two groups, either in the overall population (three [2%] of 166 in the taselisib group vs one [1%] of 168 in the placebo group; OR 3·07 [95% CI 0·32–29·85], p=0·37) or in the PIK3CA-mutant cohort (one patient [1%) vs none [0%]; OR not estimable, p=0·48). The most common grade 3–4 adverse events in the taselisib group were gastrointestinal (13 [8%] of 167 patients), infections (eight [5%]), and skin–subcutaneous tissue disorders (eight [5%]). In the placebo group, four (2%) of 167 patients had grade 3 or worse vascular disorders, two (1%) had gastrointestinal disorders, and two (1%) patients had grade 3 or worse infections and infestations. There was no grade 4 hyperglycaemia and grade 3 cases were asymptomatic. Serious adverse events were more common in the taselisib group (eight [5%] patients with infections and seven [4%] with gastrointestinal effects) than in the placebo group (one [1%] patient each with grade 3 postoperative wound and haematoma infection, grade 4 hypertensive encephalopathy, grade 3 acute cardiac failure, and grade 3 breast pain). One death occurred in the taselisib group, which was not considered to be treatment-related. Interpretation: The increase in the proportion of patients who achieved an objective response from the addition of taselisib to endocrine therapy in a neoadjuvant setting is consistent with the clinical benefit observed in hormone receptor-positive, HER2-negative, metastatic breast cancer. Funding: Genentech and F Hoffmann-La Roche.

Original languageEnglish
Pages (from-to)1226-1238
Number of pages13
JournalThe Lancet Oncology
Issue number9
StatePublished - Sep 2019

Bibliographical note

Funding Information:
CS reports grants to her institution from Roche–Genentech, Macrogenics, Pfizer, Piqur Therapeutics, Puma Biotechnology, Synthon Biopharmaceuticals, and Novartis; and personal fees from Puma Biotechnology, Pfizer, Roche, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Genomyc Health, Novartis, Pierre Fabre, and Synthon Biopharmaceuticals. DH and AJ-H report donations for trial funding from Roche–Genentech to their institution. MO reports grants from Roche–Genentech and grants from Philips Healthcare to their institution; and personal fees from Roche–Genentech, GSK, Puma Biotechnology, Novartis, Pierre Fabré, GP Pharma, and Grunenthal Group. DZ reports grants from Roche, Novartis, Astra Zeneca, and Pfizer. PN reports personal fees from Bayer, MSD, and Novartis. JML reports advisory board fees from AstraZeneca, and personal fees from Roche. PV reports personal fees and non-financial support from Roche, MSD, Novartis, BMS, Lilly, Amgen, Astra Zeneca, and Pharmamar. MC reports advisory board consultancy fees from AstraZeneca, Pierre Fabre, Pfizer, OBI Pharma, Puma Biotechnology, and Celldex; and honoraria from Novartis. EC reports personal fees from Roche; and personal fees from Lilly, Pfizer, Pierre Fabre, Celgene, and Novartis. MF reports consulting fees from Agendia and Eisai. KB reports personal fees from Pfizer, Roche, Lilly, and Novartis. AB reports a research grant from Biothernostics; and declares consultancy–advisory board services from Roche–Genentech, Immunomedics, Novartis, Prizer, Merck, Pfizer, Radius Health, Spectrum Pharma, Taiho Pharm, and Sanofi. TRW is an employee of Genentech and has stocks in Roche. JYH is an employee of Genentech with company stock and options. MP reports grants to her institution from Roche–Genentech and GSK–Novartis; and personal fees from Roche–Genentech and GSK–Novartis. MG reports personal fees and non-financial support from Amgen, Celgene, Medison, and Eli Lilly; grants, personal fees, and non-financial support from AstraZeneca, Novartis, and Pfizer; personal fees from NanoString Technology; grants and personal fees from Roche; non-financial support from Ipsen; and an immediate family member employed by Sandoz. JB reports non-financial support from Roche–Genentech (reasonable reimbursement for travel and advisory board consulting); personal fees and stock as member of the board of directors from Aura Biosciences, Northern Biologics (f/k/a Mosaic Biomedicals), Infinity Pharmaceuticals, ApoGen Biotechnologies, PMV Pharma, Juno Therapeutics, TANGO (f/k/a Synthetic Lethal), GRAIL, Varian Medical Systems, Seragon, and Venthera; stock as member of the board of directors from Foghorn Therapeutics; personal fees and non-financial support from Novartis and Eli Lilly; and personal fees and full time employee of Astra Zeneca from January, 2019; in addition, JB reports a patent for combination therapy using PDK1 and PI3K inhibitors pending, a patent for use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations licensed, and a patent for inhibition of KMT2D for the treatment of breast cancer pending for Memorial Sloan Kettering Cancer Center. EdA reports grants from Roche–Genentech to his Institution; personal fees from Roche–Genentech; and travel grants from Roche–Genentech and GSK/Novartis. Ldl-P, PD, CAC, G-B, AB, TJS, and YS declare no competing interests.

Funding Information:
The sponsor (Genentech) provided financial support for all study-related activities. The sponsor had no access to the full database before the release of the results by the Steering Committee. We acknowledge the contribution of all investigators, sites, groups (ie, Austrian Breast & Colorectal Cancer Study Group, Solid Tumors Intensive Therapy?Grupo Espa?ol de Estudio y Tratamiento de Intensificaci?n de Tumores S?lidos, Breast International Group, Chilean Cooperative Group for Oncologic Research, International Breast Cancer Study Group, Breast Cancer Trials, European Organisation for Research and Treatment of Cancer, Grupo de Estudios Clinicos Oncologicos Peruano, Gruppo Oncologico Italiano di Ricerca, and Latin American Cooperative Oncology Group), patients, and their families. We acknowledge Roche Molecular Diagnostics (Pleasanton, CA, USA) for development of the Cobas PIK3CA Mutation Test (research use only).

Publisher Copyright:
© 2019 Elsevier Ltd


Dive into the research topics of 'Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.

Cite this